A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Trial ID or NCT#
NCT06007690
Status
RECRUITING
Purpose
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Official Title
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Investigator(s)
Prithvi Mruthyunjaya, MD, MHS
Ophthalmologic oncologist,
Retina specialist,
Ophthalmologist
Alan Adler Professor of Ophthalmology and Professor, by courtesy, of Radiation Oncology
Contact us to find out if this trial is right for you.
Contact
Naz Jehangir
View on